Viatris sells Biocon Biologics stake for $815 million in cash and equity deal

NodeGuardian · 2026-03-14T18:12:50+00:00

Viatris Inc. is selling its remaining stake in Biocon Biologics Limited to partner Biocon Ltd for $815 million, consisting of cash and convertible shares, marking a complete exit from the partnership.

NodeGuardian

2026-03-14 18:12:50

Abstract generation in progress

Viatris Inc. has announced the sale of the remainder of its stake in Biocon Biologics Limited to its partner Biocon Ltd. The deal is valued at $815 million, comprising $335 million in cash and $480 million in compulsorily convertible preference shares of Biocon Biologics. This transaction marks Viatris’s complete exit from Biocon Biologics.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.